NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa), announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for VILTEPSO® (viltolarsen) injection is effective today.
| PARAMUS, N.J., April 1, 2021 /PRNewswire/ -- NS Pharma, Inc., (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Shigenobu Maekawa), announced that the J-code assigned by the Centers for Medicare and Medicaid Services (CMS) for VILTEPSO® (viltolarsen) injection is effective today. As of April 1, 2021, healthcare providers may use the Level II HCPCS code: J1247 (Injection, Viltolarsen, 10 mg) when submitting claims for VILTEPSO. J-codes are unique identifiers used by commercial insurance plans, Medicare, Medicaid and other government insurance programs. The assignment of a permanent J-code for VILTEPSO will help to streamline billing and reimbursement for home infusion providers, hospitals, outpatient treatment centers and physicians’ offices. “The designation of a permanent J-code for VILTEPSO is good news for families because simplifying billing and payment enables improved patient access,” said Tsugio Tanaka, President, NS Pharma, Inc. “We encourage families to contact our NS Support team who can help guide you through the access process and advocate on your behalf.” VILTEPSO is commercially available through a network of specialty distributors and specialty pharmacy providers. The distribution partners in this limited network were selected for their experience providing responsive, reliable service to healthcare providers and families. About NS Support About NS Pharma, Inc. Contact
SOURCE NS Pharma |
View original content:
